Arcutis Biotherapeutics stock poised for growth with 196% sales increase in skin drug sales

jueves, 17 de julio de 2025, 12:30 pm ET1 min de lectura
ARQT--

Arcutis Biotherapeutics stock is trending higher in a base after reporting a 196% growth in skin disorder drug sales. The biotech company's bottom line is improving, with expected profitability on the horizon. As a result, Arcutis is an IBD 50 Growth Stocks To Watch pick for Thursday.

Arcutis Biotherapeutics stock poised for growth with 196% sales increase in skin drug sales

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios